Mizuho

Mizuho Securities has lowered its rating of the company to Neutral from Buy and cut the price target on its stock nearly in half to $6.50 from $12.

Mizuho and William Blair downgraded Bruker, following the resignation of CFO Charles Wagner, who was noted for his role in implementing a turnaround at the company.

NEW YORK (GenomeWeb) – Piper Jaffray and Mizuho Securities today initiated coverage of transplant molecular diagnostics firm CareDx with bullish views of the company's stock and market opportunities for its tests.

NEW YORK (GenomeWeb) – Investment bank Mizuho Securities has upgraded shares of Fluidigm from Neutral to Buy citing improved end markets and the expected effects from the firm's recent acquisition of DVS Sciences.

NEW YORK (GenomeWeb News) – Mizuho Securities today upgraded shares of Myriad Genetics to a Buy rating, citing an increase in Medicare reimbursements for the BRACAnalysis test, as well as stabilized competition, and several potential positive catalysts over the next year to 24 months.

There is "still a lot to like" about Affymetrix, according to Peter Lawson.

NEW YORK (GenomeWeb News) – Investment firm Mizuho today downgraded Waters, citing "choppiness around the pharmaceutical market" that may cause the company's stock to "languish."

NEW YORK (GenomeWeb News) – Investment bank Mizuho Securities today initiated coverage of synthetic biology firm Intrexon with a Buy rating and a price target on the company's shares of $30.

Two-thirds of laboratories planning to purchase a sequencer within the next 12 months are considering Illumina's MiSeq, according to a recent survey by investment firm Mizuho Securities USA and GenomeWeb.

Pages

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.